- St. John’s-based Pelorus is raising Venture NL III, a CA$50 million local tech fund with about CA$20 million already committed, including CA$15 million from the province and CA$5 million from Klister Credit.
- Across its first two funds and SPVs, Pelorus has invested about CA$30.3 million in 16 Newfoundland and Labrador startups, with 11 still active and a reported CA$1.59 billion portfolio valuation.
- Recent breakout financings for portfolio companies include CoLab Software’s US$72 million round and Spellbook’s US$50 million raise, reinforcing Pelorus’s focus on scaling homegrown winners.
- Biotech bet Sequence Bio has a 10-year benefits and tiered gross-revenue royalty deal with the provincial government as it advances multiple genetics-driven disease studies.
Read More
Pelorus Venture Capital has demonstrated a strong track record in fueling the growth of Newfoundland and Labrador’s tech ecosystem. The firm’s strategy of local, pre-seed and seed stage investments has yielded meaningful returns, and the planned Venture NL III fund is positioned to scale that momentum. The combination of government backing, anchor private commitments (e.g., Klister Credit), and prior performance (Venture NL I’s 10-year return of 1.5×) illustrate an investor ecosystem increasingly confident in the province’s startup potential. ([entrevestor.com](https://entrevestor.com/%20home/entry/pelorus-launches-venture-nl-iii-funding-drive?utm_source=openai))
Strategically, Pelorus is leveraging both biotech/genomics strength (e.g., Sequence Bio) and emerging AI/engineering software companies (e.g., CoLab, Spellbook), diversifying sector risk while playing to regional specialization. Sequence Bio’s royalty agreement with government helps align social, political, and economic incentives—ensuring local capacity, job creation, and benefits flow back to NL. ([sequencebio.com](https://www.sequencebio.com/press/release/benefits-royalty-agreement/?utm_source=openai))
From an investment banking perspective, the key value creation levers appear to be: accelerating these “mega-deal” exits or follow-on rounds; ensuring high governance and commercial readiness in local startups; and attracting follow-on institutional capital. The depth of the portfolio (16 companies, with 11 active) and a CA$1.59 billion valuation suggest exit pipelines might include M&A or cross-border expansion. The new fund’s CA$50 million size, while modest compared to global VCs, is meaningful in NL context and may catalyze private co-investment and participation from larger national players. ([entrevestor.com](https://entrevestor.com/%20home/entry/pelorus-launches-venture-nl-iii-funding-drive?utm_source=openai))
However, several open questions remain: Can VNL III deploy capital effectively in a way that avoids over-dilution or saturation in a small ecosystem? What support infrastructure (talent, legal, regulatory, clinical trials, IP) will local firms need to scale globally? How sustainable is government funding going forward, and what governance safeguards exist to preserve performance under public-private investment pressure? Moreover, biotech-heavy investments like Sequence Bio may carry regulatory, reimbursement, and long development-cycle risks that need specialized mitigation strategies.
Supporting Notes
- Pelorus manages Fund I & II, focused on pre-seed & seed stage startups in NL; manages Venture NL I & II jointly with provincial government, BDC and angel investors. ([pelorusvc.com](https://www.pelorusvc.com/?utm_source=openai))
- Venture NL III aims for CA$50 million; already has CA$20 million committed. ([entrevestor.com](https://entrevestor.com/%20home/entry/pelorus-launches-venture-nl-iii-funding-drive?utm_source=openai))
- The government of Newfoundland and Labrador committed CA$15 million; Klister Credit pledged CA$5 million toward VNL III. ([entrevestor.com](https://entrevestor.com/%20home/entry/pelorus-launches-venture-nl-iii-funding-drive?utm_source=openai))
- Venture NL I was CA$14 million and has returned CA$21 million over 10 years (i.e., a 1.5× multiple). ([entrevestor.com](https://entrevestor.com/%20home/entry/pelorus-launches-venture-nl-iii-funding-drive?utm_source=openai))
- Pelorus has invested CA$30.3 million across 16 companies; 11 still active; portfolio valuation at CA$1.59 billion. ([entrevestor.com](https://entrevestor.com/%20home/entry/pelorus-launches-venture-nl-iii-funding-drive?utm_source=openai))
- Two large rounds in its portfolio: CoLab raised US$72 million; Spellbook raised US$50 million. ([entrevestor.com](https://entrevestor.com/%20home/entry/pelorus-launches-venture-nl-iii-funding-drive?utm_source=openai))
- Sequence Bio has signed a 10-year benefits and royalty agreement with NL government: 1% of first CA$5 million gross revenue, 1.5% for CA$5-25 million, 2% beyond. ([sequencebio.com](https://www.sequencebio.com/press/release/benefits-royalty-agreement/?utm_source=openai))
- Sequence Bio is based in St. John’s and conducts research on NL founder population, focusing on disease uses such as idiopathic pulmonary fibrosis, ovarian cancer, multiple sclerosis. ([sequencebio.com](https://www.sequencebio.com/research?utm_source=openai))